Investigation of Efficacy and Acquired Resistance for EGFR-TKI plus Bevacizumab as First-Line Treatment in Patients with EGFR Sensitive Mutant Non-Small Cell Lung Cancer in a Real World Population
Lung cancer is the leading cause of cancer-related deaths worldwide [1]. A significant proportion of patients with non-small cell lung cancer (NSCLC), particularly those with adenocarcinoma histology, carry EGFR mutations, with about 15% in Caucasian adenocarcinoma and 50% in Asian adenocarcinoma are EGFR mutants [1 –3]. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been established as the standard therapy in the first-line treatment of advanced NSCLC with EGFR mutations.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Liang Zeng, Lili Xiao, Wenjuan Jiang, Haiyan Yang, Dandan Hu, Chen Xia, Yizhi Li, Chunhua Zhou, Yi Xiong, Li Liu, Dehua Liao, Rui Guan, Kunyan Li, Jing Wang, Yongchang Zhang, Nong Yang, Aaron S. Mansfield Source Type: research
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer